Q-Line Biotech Reports Financial Results for Fiscal Year Ended March 31, 2026
Q-Line Biotech Limited, formerly known as Q-Line Biotech Private Limited, announced the results of its standalone and consolidated financial statements for the year ended March 31, 2026. The company's Board of Directors approved these results at a meeting held on June 17, 2026.The published results showcase a comprehensive view of the company’s financial health across both individual operations and overall group performance. Key statements reviewed include the Profit and Loss Statement and the Balance Sheet for the period ending March 31, 2026.
Financial Performance Highlights (Consolidated)
Q-Line Biotech reported significant results in its consolidated financial statement for the year ended March 31, 2026, compared to the same period in the previous fiscal year.The Consolidated Profit & Loss Statement data is presented below:
| Particulars | Year Ended March 31, 2026 (lakh rupees) | Year Ended March 31, 2025 (lakh rupees) |
|---|---|---|
| Total Revenue (I+II) | 34,743.90 | 32,197.33 |
| Profit Before Tax | 7,354.15 | 5,743.33 |
| Net Profit for the Period | 5,572.17 | 1,921.11 |
| Earnings Per Share (Basic) | 34.79 | 12.20 |
Consolidated Financial Position and Cash Flow
As of March 31, 2026, the consolidated balance sheet reflected a total equity and liabilities figure of 55,868.57 lakh rupees. The company's share capital stood at 1,627.50 lakh rupees, while Reserves and Surplus were reported at 22,991.70 lakh rupees.The Consolidated Statement of Cash Flow for the year ending March 31, 2026, demonstrated operational cash generation:
| Metric | Value (lakhs) |
|---|---|
| Net Profit before taxation | 7,254.97 |
| Operating Profit before Working Capital changes | 10,310.23 |
| Cash Generated from Operations | 4,240.27 |
| Net Cash inflow/(outflow) from Operating activities (A) | 1,637.55 |
Standalone Financial Results
The standalone results for the half year and financial year ended March 31, 2026, showed revenue growth in key operational areas. For the full financial year ending March 31, 2026, the company reported Total Revenue of 34,115.84 lakh rupees, with a Profit Before Tax of 7,519.49 lakh rupees and a Net Profit for the Period of 5,694.88 lakh rupees. The Earnings Per Share (Basic) for this period stood at 36.16 in Rs.Segment-wise Performance Summary
Q-Line Biotech provided segment disclosures regarding its operations under Biochemistry Reagents, Instruments and Consumables. Key figures relating to the Sale of Product Manufactured and Sale of Traded Goods are summarized in the table below:| Segment | Metric | Half Year Ended 31-03-26 | Half Year Ended 30-09-25 | Half Year Ended 31-03-25 | Year Ended 31-03-26 | Year Ended 31-03-25 |
|---|---|---|---|---|---|---|
| Sale of Product Manufactured (Revenue) | Amount (lakhs) | 14,068.88 | 8,953.77 | 12,356.92 | 23,022.65 | 16,897.01 |
| Sale of Traded Goods (Revenue) | Amount (lakhs) | 5,724.88 | 5,426.04 | 9,297.68 | 11,150.92 | 14,417.36 |
| Total Net Sales or Income from Operation | Amount (lakhs) | 19,793.76 | 14,379.81 | 21,654.60 | 34,173.57 | 31,314.37 |
| Total Profit Before Tax | Amount (lakhs) | 4,630.40 | 2,624.57 | 2,220.94 | 7,254.97 | 3,473.78 |
The results for the half year ending March 31, 2026, were audited by the company's statutory auditor. The company also provided internal audit reports and management-certified financial statements detailing operational aspects and compliance with accounting standards for its financial reporting periods.
QLINE Stock Price Movement
Q-Line Biotech Limited's shares edged higher, settling at ₹509.65 on Wednesday after gaining 1.96% in daily trading. The stock saw a total of 153,200 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.